ANGPTL3 Inhibition
Definition
Angiopoietin-like protein 3 (ANGPTL3) is a liver-exclusive hepatokine that inhibits both lipoprotein lipase (LPL) and endothelial lipase (EL), thereby raising plasma TG and HDL-C respectively. Loss-of-function variants cause familial combined hypolipidemia — a Mendelian condition with pan-lipid lowering and strong protection against coronary artery disease. Pharmacological inhibition replicates this genetic phenotype and represents a validated target for residual ASCVD risk reduction beyond statins/PCSK9 inhibitors.
Key Concepts
Biology and Mechanism
- ANGPTL3 is a 460 amino acid protein encoded on chromosome 1p31.1–p22.3; exclusively synthesised in the liver; expression regulated by the oxysterol-responsive LXR (sources/angptl3-inhibition-tcm-2024 — high)
- Undergoes furin-mediated cleavage in the linker region releasing N-terminal coiled-coil domain and C-terminal fibrinogen-like domain; O-glycosylation adjacent to linker inhibits cleavage
- Mature N-terminal fragment inhibits: (1) LPL → elevated plasma TG; (2) endothelial lipase → reduced HDL phospholipid catabolism → elevated HDL-C. ANGPTL4/8 regulate LPL only (sources/angptl3-inhibition-tcm-2024 — high)
- ANGPTL8 complex: ANGPTL8 forms a complex with ANGPTL3 potentiating LPL inhibition; ANGPTL3/8 complex is a more potent LPL inhibitor than either protein alone (sources/angptl3-inhibition-tcm-2024 — high)
- ANGPTL3 promotes preferential TG uptake in white adipose tissue while suppressing TRL clearance in oxidative tissues (heart, skeletal muscle, brown adipose tissue) — relevant to adipose tissue energy homeostasis (sources/angptl3-inhibition-tcm-2024 — high)
- LDLR-independent LDL-C lowering: Inhibition of ANGPTL3 lowers LDL-C through EL-dependent VLDL clearance — independent of LDLR-mediated endocytosis. This explains evinacumab efficacy in HoFH patients with absent LDLR function (sources/angptl3-inhibition-tcm-2024 — high; sources/gene-editing-acc-2026 — very high)
Genetic Evidence for Cardiovascular Protection
- Familial combined hypolipidemia (Musunuru 2010, NEJM; WES): E129X and S17X nonsense ANGPTL3 variants; heterozygotes — LDL-C 72 vs 109 mg/dL, TG 64 vs 130 mg/dL; compound heterozygotes — LDL-C 33 mg/dL, TG 21 mg/dL; autosomal dominant, gene-dosage effect confirmed (sources/angptl3-inhibition-tcm-2024 — high)
- GWAS: Multiple polymorphisms near ANGPTL3 (rs1748195, rs12130333, rs2131925) associated with plasma TG in large population studies (sources/angptl3-inhibition-tcm-2024 — high)
- DiscovEHR (n=58,335): 246 heterozygous ANGPTL3 LOF individuals (frequency 0.42%); OR 0.59 (P=0.004) for CAD across 4 independent cohorts (Copenhagen, Duke, Penn, TAICHI; n=23,317 CAD + 107,166 controls) (sources/angptl3-inhibition-tcm-2024 — high)
- MI Genetics Consortium (n=21,980 CAD + 158,200 controls; 9 case-control studies): ANGPTL3 LOF heterozygotes — reduced TC, HDL-C, LDL-C, TG; decreased incident CAD OR 0.66 (P=0.04); 3 compound heterozygote family members had no coronary atherosclerosis on CT angiography (sources/angptl3-inhibition-tcm-2024 — high)
- Pakistan Risk of MI Study: Lowest vs highest ANGPTL3 protein tertile → OR 0.65 (P<0.001) for incident MI (sources/angptl3-inhibition-tcm-2024 — high)
Pharmacological Approaches — Monoclonal Antibodies
| Trial |
Phase |
N |
Population |
Duration |
LDL-C ↓ |
TG ↓ |
| Gaudet et al. |
1 |
9 |
HoFH |
26 wk |
49% |
47% |
| Dewey et al. |
1 |
83 |
Mild-moderate dyslipidemia (TG 150–450 or LDL-C ≥100) |
21 days |
23% |
76% |
| Ahmad et al. (SAD) |
1 |
83 |
Hypertriglyceridemia (TG >150–450 + LDL-C ≥100) |
126 days |
21% |
88% |
| Ahmad et al. (MAD) |
1 |
56 |
Hypertriglyceridemia |
6 months |
25% |
88% |
| Rosenson et al. |
2 |
272 |
Refractory hypercholesterolemia |
16 wk |
56% |
62% |
| Raal et al. |
3 |
65 |
HoFH (LDL-C ≥70 mg/dL on max LLT) |
24 wk |
47% |
55% |
- Evinacumab (REGN1500): fully human anti-ANGPTL3 mAb (VelocImmune platform); IV 15 mg/kg q4wk standard dose; FDA-approved 2021 for HoFH ≥12 years on maximum tolerated LLT; identical EMA approval (sources/angptl3-inhibition-tcm-2024 — high)
- Raal Phase 3 — null-null LDLR: −43.4% LDL-C vs +16.2% placebo; non-null: −49.1% vs −3.8% — robust LDLR-independent effect confirmed in both genotypes (sources/angptl3-inhibition-tcm-2024 — high)
- Anti-ANGPTL3/8 dual antibody: potently blocks ANGPTL3/8-mediated LPL inhibition; reduces TG in hypertriglyceridemic mice; early development only (sources/angptl3-inhibition-tcm-2024 — high)
Pharmacological Approaches — ASO and siRNA
| Trial |
Phase |
N |
Population |
Duration |
LDL-C ↓ |
TG ↓ |
| Graham et al. (IONIS-ANGPTL3-LRx) |
1 |
44 |
LDL-C ≥70, TG ≥90 |
15–43 days |
33% |
63% |
| Gaudet et al. (vupanorsen) |
2a |
105 |
T2DM + hepatic steatosis + TG >150 |
25–27 wk |
12% |
44% |
| Bergmark et al. (TRANSLATE-TIMI 70; vupanorsen) |
2b |
286 |
Non-HDL-C ≥100 + TG 150–500 |
24 wk |
17% |
59% |
| Watts et al. (ARO-ANG3) |
1 |
30 |
Healthy volunteers |
85 days |
27% |
54% |
- Vupanorsen discontinued: TRANSLATE-TIMI 70 showed dose-dependent liver fat accumulation and ALT/AST elevation → development halted; upstream mRNA knockdown in liver may have different hepatic consequences than ANGPTL3 protein inhibition (sources/angptl3-inhibition-tcm-2024 — high)
- ARO-ANG3 (siRNA; Arrowhead): Phase 1 −45% to −78% ANGPTL3; no adverse liver fat changes; ARCHES-2 Phase 2b ongoing (NCT05217667; HoFH); interim at 16 weeks: dose-dependent ANGPTL3 reduction (up to −71%) and TG reduction (up to −59%) (sources/angptl3-inhibition-tcm-2024 — high)
- GalNAc conjugation provides hepatic specificity via asialoglycoprotein receptor uptake but cannot target ectopic ANGPTL3 expression outside hepatocytes (theoretical limitation vs mAb)
Pharmacological Approaches — Gene Editing
- BE3-Angptl3 (Chadwick et al.; murine pre-clinical): 3rd-generation base editor + gRNA targeting Angptl3 Gln135; median 35% editing rate; no off-target mutagenesis at 10 top sites; −49% ANGPTL3, −31% TG, −19% LDL-C vs control (sources/angptl3-inhibition-tcm-2024 — high)
- Clinical gene editing — see concepts/Lipid-Gene-Therapy: CTX310 (CRISPR-Cas9; Phase 1; 15 patients): LDL-C −49%, TG −55%; VERVE-201/Pulse-1 (adenine base editor via GalNAc-LNP; Phase 1b; HoFH indication — LDLR-independent advantage) (sources/gene-editing-acc-2026 — very high)
Pharmacological Approaches — Vaccines
- VLP-based vaccine encapsulating ANGPTL3 peptide aa32-47 (LPL-binding domain): robust TG clearance and enhanced LPL activity in mice; 30-week antibody production sustained in ob/ob model; no major cytotoxic autoimmune responses (sources/angptl3-inhibition-tcm-2024 — high)
- Attenuated atherosclerosis in severe FH mouse model; human translation not yet established
- ANGPTL3 LOF variants associated with increased insulin sensitivity and lower HOMA-IR (S17X homozygotes)
- Pharmacological inhibition ≠ genetic LOF on glycemia: vupanorsen 6-month treatment did NOT improve glycemic parameters or hepatic steatosis — insulin sensitivity benefit of genetic LOF may not translate to pharmacological inhibition (sources/angptl3-inhibition-tcm-2024 — high)
Contradictions / Open Questions
- No cardiovascular outcomes data: Evinacumab FDA/EMA approval is based on surrogate endpoint (LDL-C) in HoFH. Whether pharmacological ANGPTL3 inhibition reduces MACE in broader populations (residual ASCVD risk, mixed dyslipidemia) is unknown (sources/angptl3-inhibition-tcm-2024 — high)
- TG vs LDL-C mechanism for cardioprotection: Whether the cardioprotective effect of ANGPTL3 LOF is driven by LDL-C lowering, TG/remnant lowering, or the LDLR-independent LDL-C pathway remains unclear — has implications for which patient populations benefit most (sources/angptl3-inhibition-tcm-2024 — high)
- Vupanorsen hepatotoxicity vs protein-level safety: Vupanorsen (ASO targeting mRNA) caused liver fat accumulation and enzyme elevation; evinacumab (protein-level inhibition) appears safe — whether this reflects an on-target hepatic effect of ANGPTL3 knockdown at high ASO doses or an off-target drug effect is not established (sources/angptl3-inhibition-tcm-2024 — high)
- Glycemic benefit of genetic LOF not reproduced pharmacologically: ANGPTL3 LOF variants associate with better insulin sensitivity in population studies, but pharmacological inhibition (vupanorsen 6 months) did not improve glycemia — mechanism of discordance unclear (sources/angptl3-inhibition-tcm-2024 — high)
- LDLR-independent mechanism detail: EL-dependent VLDL clearance pathway explains some LDL-C lowering, but whether increased LPL activity by ANGPTL3 inhibition also contributes to LDL metabolism remains an ongoing area of study (sources/angptl3-inhibition-tcm-2024 — high)
- Antidrug antibodies and adherence: Monoclonal antibodies risk antidrug antibody development (as seen with some PCSK9 mAbs); frequent IV administration challenges real-world adherence; siRNA/ASO require less frequent dosing but have emerging safety signals (sources/angptl3-inhibition-tcm-2024 — high)
Connections
Sources